The global genetherapy market , valued at USD 4.20 billion in 2025, is projected to reachUSD ​​6.07 billion in 2026 and USD 20.47 billion by 2035, with a 14.5% CAGRduring the forecast period 2026 to 2035.

It is worth highlighting that, more than 390 gene therapieshave either received regulatory approval or are currently being evaluated inacross various phases of clinical trials to assess the safety and effectiveness of these medications in patients diagnosed with different types of inherited disorders. In fact, close to 5% of the gene therapies have already been marketed, of which 30% of the therapies are intended for the treatment of various hematological disorders that are caused due to abnormalities in specificgenes of an individual.
Additionally, at present, 920 gene therapies are either in discovery stage or being evaluated in preclinical studies, of which 60% of the therapies are being developed to be delivered using adeno-associated virus vectors. Further, during our research, we identified 345 gene therapy developers / gene therapy companies that are engaged in the development of gene therapies. The majority(58%) of gene therapy developers were established during the period 2011-2020.This period has seen a notable increase in the number of players entering the gene therapy domain, reflecting a stable and encouraging industry for the new entrants.

In fact, the positive clinical outcomes demonstrated by these therapies in real-world scenarios have attracted several start-ups to enter the domain. As such, it is worth mentioning that since 2020, close to 30developers have entered the market, indicating the growing interest of stakeholders in this field. Notable examples of such players (in reversechronological order) include Addimmune (2023), Stemcardia (2023), CelosiaTherapeutics (2022), Theriva Biologics (2022), Borea Therapeutics (2021), GromitTherapeutics (2021) and Ray Therapeutics (2021).

Close to 80% of the marketed and clinical stage genetherapies have received orphan drug designation. This can be attributed to the fact that around 80% of rare diseases worldwide are genetic in nature. , Hence, in order to overcome the burden associated with these conditions, regulatorybodies have proactively granted orphan drug designations (granted to drugs developed for the treatment of rare diseases) to gene therapies that have demonstrated clinical efficacy in addressing the underlying genetic cause of such orphan indications. This is followed by gene therapies that have receivedfast track designation (48%) and rare pediatric disease designation (31%).

Further, close to 90% of marketed and clinical stage genetherapies are delivered using the in vivo method primarily due to the fact that in vivo gene delivery is typically a simpler process, which involves direct administration of genetic material to the target organ within the body.Moreover, unlike ex vivo gene therapies, in vivo gene delivery is aless-invasive process, as it minimizes the need for procedures such as cellextraction and in vitro genetic modification; thereby maximizing the patient compliance to these gene therapies. Further, over 10% of the gene therapies that are currently being developed are delivered using ex vivo methods. Examples of marketed gene therapies delivered through ex vivo method (arranged inalphabetical order) includes Casgevy™ (CRISPR Therapeutics and VertexPharmaceuticals), INVOSSA® (Kolon TissueGene) and Libmeldy™ (OrchardTherapeutics and SR-Tiget).

Majority (60%) of preclinical and discovery stage genetherapies are delivered using adeno-associated virus vectors. This is followed by therapies delivered using non-viral vectors (14%) and lentivirus vectors(7%). Notable examples of gene therapies delivered using non-viral vectors(arranged in alphabetical order, being developed for treatment of genetic disorders) include CS-104 (CorrectSequence Therapeutics), EG-i08 (enGene),GF-1003 (Genflow Biosciences) and RY107 (Reyon Pharmaceutical and MDimune)

Further, a maximum (23%) of the preclinical and discovery stage gene therapies are being developed for the treatment of neurological disorders. It is important to note that neurological disorders are currently the second leading cause of death worldwide. In fact, according to the WorldFederation of Neurology, in 2023, over 40% of the global population had suggested from some form of neurological conditions and these statistics are likely to double by 2050. As a result, there is an alarming need to develop effective therapies that can target the root cause of these diseases and can address the current unmet needs. In this regard, gene therapies have emerged as a promising therapeutic modality as they are designed to cross the blood-brain barrier and deliver functional genes, potentially treating a range of inheritedneurological disorders.

Research Methodology
Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of datacollection. The report has gathered the necessary data and information fromseveral reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them achieve a competitive edge in the Gene Therapy Market.

Thank you for reading our report. Kindly get in touch withus to know more about the report or to receive a customized copy of it. Ourteam will ensure the report is tailored according to your needs.

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/gene-therapies-market/268.html